Copaxone, which was released in 2014, is a treatment for multiple sclerosis marketed by TEVA Pharmaceuticals, and is the only drug prepared by NCA-polymerization that is FDA approved. Ring opening polymerization is a more practical approach for large-scale production of polypeptides where sequence specificity is less important than bulk physical properties.[1][2]